|
To address the complexity of both minimizing the transmission of
VRE, MRSA, and C. difficile in the inpatient psychiatric
setting through infection control measures with the needs of the
patient's psychiatric treatment plan, the following measures are
to be implemented for patients known to be colonized or infected
with vancomycin-resistant enterococci (VRE), methicillin-resistant
Staphylococcus aureus (MRSA), C. difficile (infection
only), and other epidemiologically significant organisms transmitted
by direct or indirect contact.
Identification
As
part of the intake process, inpatient transfers shall be screened
for the presence or absence of VRE, MRSA, C. difficile,
and/or other epidemiologically significant organisms through review
of the medical record and/or the presence of Contact Precautions
in use. The site(s) where the resistant organism is located, the
presence or absence of infected bodily secretions/excretions which
can or cannot be contained and the patient’s ability to comply
with directions are to be noted before transfer. Outpatients admitted
directly or via the Crisis Intervention Unit shall be screened using
the automated resistant organism file in CCSS which is activated
at the time a bed is booked for admission. If a patient is identified
as having a history of VRE, MRSA, and/or another epidemiologically
significant organism, the same process for determining the specific
level of precautions will be used as for inpatient transfers. All
questions regarding a patient’s history of VRE, MRSA, etc.
should be directed to YNHH Epidemiology & Infection Control
at 8-4634. If there is any doubt regarding such history, the patient
should be placed on the appropriate level of precautions as delineated
below and Hospital Epidemiology should be contacted. |